COVID-19 Spike Domain Antibody COVIDSDAB
Synonyms |
||||||||
Allscripts (AEHR) Order Name |
COVID-19 Spike Domain Antibody |
|||||||
Sunrise Clinical Manager (SCM) Order Name |
COVID-19 Spike Domain Antibody |
|||||||
EPIC Order Name |
||||||||
Clinical Info |
Intended for semiquantitative detection of antibodies to SARS‑CoV‑2 spike protein. This test is intended for use as an aid in identifying individuals with an adaptive immune response to SARS‑CoV‑2, indicating recent/prior infection and/or COVID-19 vaccination. |
|||||||
Specimen Type |
Blood |
|||||||
Container |
Gold or Lithium Heparin (Mint-green) top tube |
|||||||
Collection Instructions |
Specimen: 1.0 mL serum or plasma (0.5 mL min) |
|||||||
Transport Instructions |
Refrigerated |
|||||||
Specimen Stability |
14 days Room Temperature |
|||||||
Methodology |
||||||||
Days Performed |
Sunday - Saturday |
|||||||
Performing Laboratory |
Northwell Health Laboratories |
|||||||
CPT |
86769 |
|||||||
PDM |
2153036 |
|||||||
Result Interpretation
The Roche Elecsys Anti‑SARS‑CoV‑2 S has been approved by the FDA for Emergency Use Authorization only. It has been validated to be accurate by Northwell Health Laboratories. Positive results indicate that antibodies against SARS-CoV-2 were detected in your blood either from previous infection with SARS-CoV-2 virus and/or COVID-19 vaccination. Presence of antibodies to SARS‑CoV‑2 may not guarantee protection from SARS-CoV-2 reinfection. Negative results do not preclude SARS‑CoV‑2 infection and should not be used as the sole basis for patient management decisions. A negative result can occur if the quantity of the anti‑SARS‑CoV‑2 antibodies is below the detection limits of the assay, or the antibodies that are detected are not present during the stage of disease in which a sample is collected. Follow-up testing with a molecular diagnostic tets should be considered to rule out infection in these individuals. |
||||||||
Forms |
